Mosaic ImmunoEngineering (OTCMKTS:CPMV) Releases Quarterly Earnings Results

Mosaic ImmunoEngineering (OTCMKTS:CPMV) announced its earnings results on Tuesday. The company reported ($0.02) EPS for the quarter, Zacks reports.

Mosaic ImmunoEngineering Stock Performance

Shares of CPMV stock remained flat at $0.63 during trading hours on Tuesday. The stock had a trading volume of 6 shares, compared to its average volume of 1,068. The stock’s 50-day moving average price is $0.85 and its 200-day moving average price is $0.88. The stock has a market cap of $4.54 million, a P/E ratio of -4.18 and a beta of 0.15. Mosaic ImmunoEngineering has a 12-month low of $0.10 and a 12-month high of $1.13.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.